Molecule News and Research

RSS

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

Red wine may prevent holiday weight gain

Here's a New Year's resolution you can keep: drink more wine! It reinforces a healthier lifestyle and starting now, may prevent the holiday weight gain that is an American tradition.

18 Dec 2009

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by Swedish scientists at Uppsala University, is published in the December issue of the journal Vaccine.

17 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.

16 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

StemCells, Inc. announced today that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency (the ability to become any cell in the body, which is the defining attribute of embryonic stem cells), including the reprogramming of cells to create pluripotent stem cells.

16 Dec 2009

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Englerin A, a natural product recently discovered in an African plant, possesses high toxicity for kidney cancer cells but low toxicity for other cells. Therefore this compound is potentially qualified for further evaluation toward an application in cancer therapy.

16 Dec 2009

Nitric oxide opens up new treatment option for septic shock

Scientists at VIB and Ghent University in Flanders, Belgium have found an unexpected ally for the treatment of septic shock, the major cause of death in intensive care units.

16 Dec 2009

Drug monitoring may provide alternative treatments for patients with severe H1N1

An international team of Canadian and Spanish scientists have found the first potential immunological clue of why some people develop severe pneumonia when infected by the pandemic H1N1 virus.

16 Dec 2009

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

Alaska-Scientists identify a novel antifreeze molecule, xylomannan

Alaska-Scientists have identified a novel antifreeze molecule in a freeze-tolerant Alaska beetle able to survive temperatures below minus 100 degrees Fahrenheit. Unlike all previously described biological antifreezes that contain protein, this new molecule, called xylomannan, has little or no protein.

15 Dec 2009

RORalpha protein revealed as an essential regulator of inflammatory factors

How do the brain cells called astrocytes ensure the protection of neurons? By studying the protagonists in the protection and satisfactory functioning of neurons, scientists at the Laboratoire Neurobiologie des Processus Adaptatifs (CNRS/UPMC) have found a mechanism that clarifies the role of astrocytes.

15 Dec 2009

Champagne improves blood flow and reduces risk of cardiovascular diseases

Research from the University of Reading suggests that two glasses of Champagne a day may be good for your heart and circulation. The researchers have found that drinking Champagne wine daily in moderate amounts causes improvements in the way blood vessels function.

15 Dec 2009

Amgen receives worldwide rights to Array’s small-molecule glucokinase activator program

Array BioPharma Inc. and Amgen Inc.(NASDAQ: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.

14 Dec 2009

Scientists present new research on adipocyte regulation

The ninth Colloque Médecine et Recherche of la Fondation Ipsen devoted to Endocrinology, held in Paris on December 4, 2009, has reviewed the recent progress in understanding the regulation of fat storage in the body and the consequences of the breakdown of this regulation.

14 Dec 2009

Researchers discover enzyme activity behind sleep deprivation

There is hope for those who miss one night too many or whose children keep them up at night. The unwelcome effects of a bad night's sleep - forgetfulness, impaired mental performance - can be dealt with by reducing the concentration of an enzyme in the brain. These are the conclusions of research published by Rubicon-grant winner Robbert Havekes and colleagues in the 22 October issue of Nature.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Positive interim results of ARRY-380 in Phase 1 trial announced

Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

13 Dec 2009

Molecule News and Research

Phase 2 clinical study of STA-9090 in NSCLC initiated

Red wine may prevent holiday weight gain

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Nitric oxide opens up new treatment option for septic shock

Drug monitoring may provide alternative treatments for patients with severe H1N1

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

Alaska-Scientists identify a novel antifreeze molecule, xylomannan

RORalpha protein revealed as an essential regulator of inflammatory factors

Champagne improves blood flow and reduces risk of cardiovascular diseases

Amgen receives worldwide rights to Array’s small-molecule glucokinase activator program

Scientists present new research on adipocyte regulation

Researchers discover enzyme activity behind sleep deprivation

Texas researchers identify new detection method for circulating tumor cells

Positive interim results of ARRY-380 in Phase 1 trial announced

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News